Compare Iovance Biotherapeutics Inc. Common Stock (IOVA) vs NIO Inc. (NIO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Iovance Biotherapeutics Inc. Common Stock vs NIO Inc. — how do they compare? Iovance Biotherapeutics Inc. Common Stock trades at $14.62 (market cap $6.04B), while NIO Inc. trades at $3.58 (market cap $8.62B). The key difference: NIO Inc. is the larger of the two by market cap, and Iovance Biotherapeutics Inc. Common Stock is trading nearer its 52-week high, NIO Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Iovance Biotherapeutics Inc. Common Stock for 0 Days and NIO Inc. for 81 Days on average.
| IOVA | NIO | |
|---|---|---|
Market Cap | $6.04B | $8.62B |
Volume | 14,805,993 | 39,648,517 |
Sector | Health | Consumer Cyclical |
52-Week High | $14.82 | $7.46 |
52-Week Low | $1.81 | $3.37 |
Typical Hold Time | 0 Days | 81 Days |
Enterprise Value | $5.97B | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
NIO trades at $3.41, down 3.67% today and near its 52-week low, reflecting bearish technical signals. The company reported Q3 2026 deliveries up 25.4% but continues to post net losses, with a -4.17% net income margin in 2026. Recent news highlights a strategic battery-swap partnership with Geely, valued at $2.38 billion for NIO Power, aiming to expand charging infrastructure amid a competitive EV price war in China.
The outlook remains challenging due to persistent losses and high debt, though revenue growth and analyst consensus suggest long-term potential. Risks include intense competition, margin pressure, and macroeconomic headwinds. With a $6.23 average price target, analysts see 83% upside, but investors must weigh profitability improvements against ongoing cash burn.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Iovance Biotherapeutics Inc. Common Stock
Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →About NIO Inc.
NIO Inc. manufactures and sells automobiles. The Company offers electric vehicles and parts, as well as provides battery charging services. NIO serves customers worldwide.
Read more on NIO →
